Columvi achieved a 78.3% complete response rate and 85% overall response rate in relapsed/refractory mantle cell lymphoma ...

A trial evaluating the tamibarotene-Vidaza combination in certain patients with newly diagnosed high-risk MDS will be ...

Panelists discuss key advice for patients and caregivers navigating advanced prostate cancer, highlighting essential insights ...

Panelists discuss the key takeaways from their experiences in treating advanced prostate cancer, emphasizing valuable lessons ...

Survivorship: it’s a positive word that elicits the idea of success, winning and, as a four-time cancer survivor myself, the ...